Back Back
Eprex Injection
Get Price Quote
EPREX INJECTION synthetic erythropoietin DESCRIPTION Eprex by Jannsen is a synthetic erythropoietin used to replace the erythropoietin that is lacking in people who cannot produce enough, usually due to kidneys not functioning properly. Epoetin alfa is used to treat anemia in people with chronic kidney disease (CKD), whether or not they are on dialysis. Erythropoietin is produced naturally in the body, mostly by the kidneys. It gives bone marrow the signal to produce red blood cells (RBCs), which carry oxygen in the blood. Epoetin alfa works by causing increased red blood cell production by the body. If the body does not produce enough erythropoietin, severe anemia (lack of oxygen reaching the different parts of the body) can occur. It is available in 8 dosages that is 1000 IU, 2000 IU, 3000 IU, 4000 IU, 6000 IU, 8000 IU, 10000 IU & 40000 IU SIDE EFFECTS clotting of the vascular access site (for people on hemodialysis) dehydration diarrhea edema (swelling of the face, fingers, ankles, feet, or lower legs) headache increased or decreased blood pressure, dizziness, or feeling faint muscle aches and pain nausea signs of infection (cough, fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, sore throat, stiff neck, weight loss, or listlessness) Stop taking the medication and seek immediate medical attention if any of the following occur: chest pain seizures signs of allergic reaction (symptoms may include skin rash or hives, trouble breathing, sweating, abnormal heart rate, or decreased blood pressure) signs of blood clots (pain or swelling in the legs, worsening shortness of breath, coughing up blood) signs of stroke (confusion, severe headache, sudden weakness, dizziness, trouble speaking, or vision problems)
Erythropoietin-EPREX 1000 Iu x 0.5mL
Get Price Quote
EPREX (Epotein alfa | is used for the treatment of: anemia associated with CRF, for adults and children of hemodialysis, peritoneal dialysis * anemia in cancer patients with non-myeloid malignancies (with or without chemotherapy) anemia in HIV patients, including. treated with zidovudine, whose endogenous erythropoietin levels are less than 500 mU ml
0.0
View Profile
Best Deals from Eprex Injection
Eprex Injection
Get Price Quote
Erythropoietin (EPO) is a glycoprotein hormone produced primarily by the kidney in response to hypoxia and is the key regulator of red blood cell (RBC) production. EPO is involved in all phases of erythroid development, and has its principal effect at the level of erythroid precursors. After EPO binds to its cell surface receptor, it activates signal transduction pathways that interfere with apoptosis and stimulates erythoid cell proliferation. Erythropoietin stimulates erythropoiesis in anaemic patients with chronic renal failure in whom the endogenous production of erythropoietin is impaired. Because of the length of time required for erythropoiesis – several days for erythroid progenitors to mature and be released into the circulation – a clinically significant increase in haemoglobin is usually not observed in less than two weeks and may require up to ten weeks in some patients. Erythropoiesis-stimulating agents ESAs are growth factors that primarily stimulate red cell production. Erythropoietin receptors may be expressed on the surface of a variety of tumour cells (see PRECAUTIONS – Use in Cancer Patients).
Eprex Injection
Get Price Quote
Erythropoietin (EPO) is a glycoprotein hormone produced primarily by the kidney in response to hypoxia and is the key regulator of red blood cell (RBC) production. EPO is involved in all phases of erythroid development, and has its principal effect at the level of erythroid precursors. After EPO binds to its cell surface receptor, it activates signal transduction pathways that interfere with apoptosis and stimulates erythoid cell proliferation.Erythropoietin stimulates erythropoiesis in anaemic patients with chronic renal failure in whom the endogenous production of erythropoietin is impaired. Because of the length of time required for erythropoiesis – several days for erythroid progenitors to mature and be released into the circulation – a clinically significant increase in haemoglobin is usually not observed in less than two weeks and may require up to ten weeks in some patients. Erythropoiesis-stimulating agents ESAs are growth factors that primarily stimulate red cell production. Erythropoietin receptors may be expressed on the surface of a variety of tumour cells (see PRECAUTIONS – Use in Cancer Patients).
Eprex 4000IU 6 Injectoin
49 - 65 Per Packet
40 Pack (MOQ)
EPREX prefilled syringes contain the active ingredient epoetin alfa, a protein that stimulates bone marrow to produce more red blood cells. Red blood cells are responsible for carrying oxygen to all parts of your body. A decrease in the number of red blood cells can cause anaemia. Some symptoms of anaemia are tiredness, breathlessness when exercising, and feeling cold.
0.0
View Profile
Eprex Injection
Get Price Quote
0.0
View Profile
Post Free Ad